ArticleBone marrow transplantation2016
Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.
Abstract readComparative Study
In one paragraph
Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Trial
- Haploidentical Stem Cell Transplantation With Dual Source of Cells and Post-Transplant Cyclophosphamide.Cancer medicine · 2025Article
- Review
- Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry.Journal of hematology & oncology · 2024Article
- Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation.Frontiers in immunology · 2024Review
- Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation.Bone marrow transplantation · 2023Article
- Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation.Journal of clinical medicine · 2021Article
- G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study.Frontiers in oncology · 2021Article
- Article
- Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Article
- Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Article
- Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes.Bone marrow transplantation · 2019Article
- Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients.Bone marrow transplantation · 2019Article
- Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results.Seminars in hematology · 2019Review
- Assessing the efficacy of an ambulatory peripheral blood hematopoietic stem cell transplant program using reduced intensity conditioning in a low-middle-income country.Bone marrow transplantation · 2019Article
- Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection.Bone marrow transplantation · 2018Review
- Article
- Review
- Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
P V O'DonnellDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
M EapenDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
M M HorowitzDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
B R LoganDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
A DiGilioDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
C BrunsteinBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.
E J FuchsSydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
M E D FlowersDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
R SalitDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
K RajGuy's and St. Thomas' Hospitals NHS Hospitals Foundation Trusts, London, UK.
A PagliucaDepartment of Haematological Medicine, King's College Hospital, London, UK.
K BradstockDepartment of Hematology, Westmead Hospital, Westmead, New South Wales, Australia.
A GranataDepartment of Hematology, Institut Paoli Calmettes (IPC), Aix Marseille University (AMU), UM105, Centre de Reserche en Cancerologie (CRCM), Inserm U1068, CNRS UMR7258, Marseille, France.
L CastagnaDepartment of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy.
S FurstDepartment of Hematology, Institut Paoli Calmettes (IPC), Aix Marseille University (AMU), UM105, Centre de Reserche en Cancerologie (CRCM), Inserm U1068, CNRS UMR7258, Marseille, France.
D BlaiseDepartment of Hematology, Institut Paoli Calmettes (IPC), Aix Marseille University (AMU), UM105, Centre de Reserche en Cancerologie (CRCM), Inserm U1068, CNRS UMR7258, Marseille, France.
Funding
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Geoffrey Roger HILL · 1985 to 2026
$128.4MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MPB vs. BMU01HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2001 to 2010
$63.3MEasy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8MSargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell MobilizationU10HL109137 · NHLBI · WASHINGTON UNIVERSITY · PI WESTERVELT, PETER · 2011 to 2016
$937kEnhancing the Safety of Allogeneic TransplantationU10HL069290 · NHLBI · UNIVERSITY OF MINNESOTA · PI WEISDORF, DANIEL J · 2011 to 2016
$931kNCI NIH HHS P01 CA018029NCI NIH HHS U24 CA076518NHLBI NIH HHS U01 HL069294NHLBI NIH HHS U10 HL069290NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U10 HL109137
Abstract
PubMed holds no abstract for this paper.
Indexed as
Bone Marrow TransplantationPeripheral Blood Stem Cell TransplantationTransplantation ConditioningAdolescentAdultAgedAge FactorsClinical Trials, Phase II as TopicCohort StudiesFemaleHematopoietic Stem Cell TransplantationHumansLeukemiaMaleMatched-Pair AnalysisMiddle Aged
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.